Ligand Pharmaceuticals (LGND) Total Non-Current Liabilities (2010 - 2026)

Ligand Pharmaceuticals has disclosed Total Non-Current Liabilities across 17 years of filings, most recently posting $517.7 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $517.7 million, up 441.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $517.7 million (up 441.19% YoY), and the FY2025 annual result was $526.8 million, up 548.99% from the prior year.
• Total Non-Current Liabilities came in at $517.7 million for Q1 2026 at Ligand Pharmaceuticals, down from $526.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $526.8 million in Q4 2025 to a low of $57.7 million in Q3 2023.
• The 5-year median for Total Non-Current Liabilities is $105.7 million (2025), against an average of $192.6 million.
• Across the five-year window, Total Non-Current Liabilities slumped 72.85% in 2023 and jumped 548.99% in 2025, its largest moves.
• Ligand Pharmaceuticals' Total Non-Current Liabilities stood at $137.4 million in 2022, then slumped by 57.4% to $58.5 million in 2023, then jumped by 38.65% to $81.2 million in 2024, then surged by 548.99% to $526.8 million in 2025, then retreated by 1.73% to $517.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $517.7 million (Q1 2026), $526.8 million (Q4 2025), and $506.7 million (Q3 2025), per Business Quant data.